Source Precision Medicine, Inc., d/b/a Source MDx Announces Source Laboratory Information Management Systems (LIMS), Source Dynamics and Source Primer/Probe Database Will Be Offered for Sale on April 29, 2011

By Joseph F. Finn Jr. C.p.a., PRNE
Tuesday, April 5, 2011

WELLESLEY HILLS, Massachusetts, April 6, 2011 - Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of
Creditors of Source Precision Medicine, Inc., d/b/a Source MDx ("Source MDx")
announced that Source Laboratory Information Management Systems (LIMS),
Source Dynamics and Source Primer/Probe Database will be offered for sale on
April 29, 2011.

The Primer/Probe database and software, for instance, is a user-friendly
interface for the repository of all primer/probe related information from
design, sequence information across multiple design versions to serial
quality control test data. The software provides a secure and audit-friendly
database that supports a metrics driven approval of reagents designed to meet
specific performance characteristics.

Finn also stated that the patent number information announced in his
March 21, 2011 press release was incorrect. Patent number 6,940,439 should
have been stated as 6,960,439.

Persons interested in bidding must sign a Confidentiality Disclosure
Agreement ("CDA") obtained from Finn's office - jffinnjr@finnwarnkegayton.com
or +1-781-237-8840. They will then receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm Finn,
Warnke & Gayton LLP of Wellesley Hills, Massachusetts
(www.finnwarnkegayton.com). He works primarily in the area of
management consulting for distressed enterprises, bankruptcy accounting and
related matters, such as Assignment for the Benefit of Creditors and
Liquidating Agent for corporations. He has been involved in a number of loan
workouts and bankruptcy cases for thirty-six (36) years. His most recent
Assignments for the Benefit of Creditors in the biotech filed include
Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc. and Epix
Pharmaceuticals, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at
+1-781-237-8840.

.

Banking and Financial Services News

April 6 News

YOUR VIEW POINT
NAME : (REQUIRED)
MAIL : (REQUIRED)
will not be displayed
WEBSITE : (OPTIONAL)
YOUR
COMMENT :